Pay in 4 interest-free payments of $6.78 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
This results in patients consuming less food and satiating earlier
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Image INDIANAPOLIS- Eli Lilly and Company (NYSE: LLY) today announced Zepbound (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand
We can support requests for export-friendly labeling, where permitted, and align secondary packaging to logistics needs
Moreover, certain clinics in larger cities or better areas could charge more than those in smaller locations
The bigger factor in real-world results is adherence
At maintenance doses of 10 to 15 mg per week, a single 30 mg vial lasts two to three weeks
US$ 21.55
US$ 22.52
US$ 28.49
US$ 28.62
US$ 24.13
US$ 27.45
US$ 27.38
US$ 26.24
